AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 14 - (NewsRx.com & NewsRx.net) -- Computer Sciences Corporation (CSC) announced that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International, a vaccine development company focused on biodefense vaccines, has completed phase I testing of the safety and immunogenicity of an improved cell-cultured smallpox vaccine (CCSV).
In this trial, 100% of 350 volunteers exhibited a positive response to either the CCSV or the historic calf lymph-produced smallpox vaccine (Dryvax). However, the incidence of vaccine-related fatigue, application site rash, increased temperature, headache, lymphangitis and nausea was at least 8% less common for volunteers receiving CCSV than Dryvax.
DVC develops biodefense vaccines for the Department of Defense (DoD) through the Joint Vaccine Acquisition Program (JVAP). This is accomplished through the design and implementation of strategies for advanced development by partnering with government and industry.
"Protection against potential future biological attacks continues to be a key concern of our nation's leaders," said DVC president Terry Irgens. "The availability of adequate stocks of effective and safe smallpox vaccine that meets modern manufacturing standards is of paramount importance. At ...
Source: HighBeam Research, Phase I smallpox vaccine clinical trial completed.